Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Europ. Pharma Outsourc...Europ. Pharma Outsourcing
Not Confirmed
Not Confirmed
05-06 June, 2025
Not Confirmed
Not Confirmed
05-06 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Europ. Pharma Outsourc...Europ. Pharma Outsourcing
Industry Trade Show
Not Confirmed
05-06 June, 2025
Industry Trade Show
Not Confirmed
05-06 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
06 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regenxbio-reports-new-positive-functional-data-from-phase-iii-affinity-duchenne-trial-of-rgx-202-302473842.html
14 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/fda-accepts-biologics-license-application-for-mucopolysaccharidosis-ii-treatment-302454515.html
12 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regenxbio-reports-first-quarter-2025-financial-results-and-recent-operational-highlights-302452862.html
19 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regenxbio-reports-positive-biomarker-data-from-affinity-duchenne-trial-of-rgx-202-gene-therapy-302405712.html
15 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regenxbio-and-nippon-shinyaku-announce-exclusive-partnership-to-develop-and-commercialize-rgx-121-and-rgx-111-for-mps-diseases-302350270.html
18 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regenxbio-initiates-pivotal-phase-of-affinity-duchenne-trial-of-rgx-202-gene-therapy-and-reports-positive-functional-data-302307989.html
ABOUT THIS PAGE